Article Text
Editorial
Withdrawal of ‘Xigris’ from the market: old and new lessons
Statistics from Altmetric.com
Footnotes
Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests DP has no conflict of interest. GB was a member of the European Medicines Agency (EMEA) Ad Hoc Expert Group for the second annual reassessment of DrotAA. SG was a member of the EMEA Committee for Medicinal Products for Human Use (CHMP) from 1997 to 2004.
Provenance and peer review Commissioned; internally peer reviewed.